Navigation Links
Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
Date:11/5/2008

oking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(R) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on the Company's ADHD franchise; patents, including but not limited to, legal challenges relating to the Company's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); the Company's ability to secure new products for commercialization and/or development; the Company's ability to successfully integrate its stake in Jerini AG, as well as realize the anticipated benefits of the acquisition; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007.

For further information please contact:

Investor Cléa Rosenfeld (Rest of the World) +44-1256-894-160

Relations

Eric Rojas (North America) +1-617-551-9715

Media Jessica Mann (Rest of the World) +44-1256-894-280

Matthew Cabrey (North America) +1-484-595-8248

Jessica Cotrone (North America) +1-617-613-4640


'/>"/>
SOURCE Shire Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... ... therapy. Two years after endovascular treatment, 88 percent of women avoided amputation compared to ... ... are at risk of lower-leg amputation fare even better than men when they have minimally ...
... divas of the nanoworld. In possession of alluring properties, ... cousins. On the plus side, they can withstand ... Yoke Khin Yap, an associate professor of physics at ... in a barbecue at half of those temperatures," he ...
... , , , , , SAN ... ), a biopharmaceutical company focused on developing and commercializing novel ... Chief Executive Officer, is scheduled to present at the 28th ... 2009 at the Westin St. Francis Hotel in San Francisco, ...
Cached Biology Technology:Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 2Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 3Harnessing the divas of the nanoworld 2NeurogesX to Present at J.P. Morgan Health Care Conference 2NeurogesX to Present at J.P. Morgan Health Care Conference 3
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
(Date:7/9/2014)... numerous inhabitants of the sea: tiny haptophytes of the ... naked eye, when they are in bloom in spring, ... visible on satellite images. "Together with other phytoplankton, ... the global photosynthesis output," states Prof. Dr. Georg Pohnert ... process the greenhouse gas carbon dioxide CO2 ...
(Date:7/8/2014)... future health of the world,s coral reefs and the ... the ability of one tiny symbiotic sea creature to ... algae it cooperates with. , In the first study ... discovered that coralstiny reef-forming animals that live symbiotically with ... heat stress, called "bleaching," when they keep large energy ...
Breaking Biology News(10 mins):Short circuit in the food web 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4
... of the Spanish Foundation for Biodiversity, the Charter Provincial Council ... R+D Centre will be studying the re-stocking of the three ... of May, June and July, respectively, in three streams of ... information needed to be able to manage the species and ...
... This release is available in German . ... Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to ... by the appropriate Grants Committee in Bonn. The new institutions ... half years, during which time they will receive total funding ...
... the Walter and Eliza Hall Institute in Melbourne, Australia, ... the UK,s peak academy promoting excellence in science. ... to the Royal Society in 2011, including four Australians. ... process on the basis of excellence in science. ...
Cached Biology News:A study will enable the survival and growth of the 3 development phases of the European eel 2DFG establishes 18 new research training groups 2DFG establishes 18 new research training groups 3DFG establishes 18 new research training groups 4DFG establishes 18 new research training groups 5DFG establishes 18 new research training groups 6DFG establishes 18 new research training groups 7DFG establishes 18 new research training groups 8DFG establishes 18 new research training groups 9DFG establishes 18 new research training groups 10Top Australian malaria researcher elected Fellow of the Royal Society 2Top Australian malaria researcher elected Fellow of the Royal Society 3
... the needs of the biopharmaceutical ... supports fast cell growth rates ... maintaining high cell viability and ... the Baculovirus Expression Vector System ...
Mol wt: average mol wt12,360.96 Da by calculation...
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
Biology Products: